GlaxoSmithKline holds dividend, eyes IPO of HIV unit

A no entry sign is pictured outside the GlaxoSmithKline building in Hounslow, west LondonLONDON (Reuters) – GlaxoSmithKline kept its dividend unchanged for the third quarter, breaking a run of steadily rising payouts, as U.S. pricing pressure on its top-selling lung drug Advair eroded sales and profit. Britain's biggest drugmaker said on Wednesday its 2015 dividend was expected to be maintained at the same level as 2014 but it plans to return an additional 4 billion pounds ($ 6.4 billion) to shareholders via a special share scheme. It also announced a further cost-cutting program and said it would explore an IPO of a minority stake in its HIV business ViiV Healthcare. …



Sexual Health News Headlines – Yahoo! News